Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

被引：116

作者：

Anker, Stefan D. ^{[1
,2
,3
]}

Butler, Javed ^{[4
]}

Filippatos, Gerasimos ^{[5
]}

Shahzeb Khan, Muhammad ^{[4
]}

Pedro Ferreira, Joao ^{[6
]}

Bocchi, Edimar ^{[7
]}

Bohm, Michael ^{[8
,9
]}

Pieter Brunner-La Rocca, Hans ^{[10
]}

Choi, Dong-Ju ^{[11
]}

Chopra, Vijay ^{[12
]}

Chuquiure, Eduardo ^{[13
]}

Giannetti, Nadia ^{[14
]}

Esteban Gomez-Mesa, Juan ^{[15
]}

Janssens, Stefan ^{[16
]}

Januzzi, James L. ^{[17
]}

Gonzalez-Juanatey, Jose R. ^{[18
]}

Merkely, Bela ^{[19
]}

Nicholls, Stephen J. ^{[20
]}

Perrone, Sergio, V ^{[21
]}

Pina, Ileana L. ^{[22
]}

Ponikowski, Piotr ^{[23
]}

Senni, Michele ^{[24
]}

Seronde, Marie-France ^{[25
]}

Sim, David ^{[26
]}

Spinar, Jindrich ^{[27
]}

Squire, Iain ^{[28
]}

Taddei, Stefano ^{[29
]}

Tsutsui, Hiroyuki ^{[30
]}

Verma, Subodh ^{[31
]}

Vinereanu, Dragos ^{[32
]}

Zhang, Jian ^{[33
]}

Jamal, Waheed ^{[34
]}

Schnaidt, Sven ^{[35
]}

Schnee, Janet M. ^{[36
]}

Brueckmann, Martina ^{[34
,37
]}

Pocock, Stuart J. ^{[38
]}

Zannad, Faiez ^{[6
]}

Packer, Milton ^{[39
,40
]}

机构：

[1] Berlin Inst Hlth Ctr Regenerat Therapies BCRT, Dept Cardiol CVK, Berlin, Germany

[2] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany

[3] Charite Univ Med Berlin, Berlin, Germany

[4] Univ Mississippi, Sch Med, Jackson, MI USA

[5] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[6] Univ Lorraine, Inserm INI CRCT, Nancy, France

[7] Univ Sao Paulo, Med Sch, Sao Paulo, Brazil

[8] Univ Saarland, Univ Klinikum Saarlandes, Homberg, Germany

[9] Univ Saarland, Med Fak, Homberg, Germany

[10] Maastricht Univ Med Ctr, Maastricht, Netherlands

[11] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea

[12] Medanta Medicity Max Superspecial Hosp, New Delhi, India

[13] Inst Nacl Cardiol Ignacio Chavez, Ciudad De Mexico, Mexico

[14] Ctr Univ Sante McGill, Montreal, PQ, Canada

[15] Fdn Valle del Lili, Cali, Colombia

[16] Univ Hosp Leuven, Leuven, Belgium

[17] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

[18] Complejo Hosp Univ Santiago, CIBERCV, La Coruna, Spain

[19] Semmelweis Univ, Budapest, Hungary

[20] Monash Univ, Victorian Heart Inst, Clayton, Vic, Australia

[21] FLENI Inst, Dept Cardiol, Buenos Aires, DF, Argentina

[22] Wayne State Univ, Detroit, MI USA

[23] Wroclaw Med Univ, Wroclaw, Poland

[24] ASST Papa Giovanni XXIII, Bergamo, Italy

[25] Ctr Hosp Reg & Univ Besancon, Besancon, France

[26] Natl Heart Ctr, Singapore, Singapore

[27] Masaryk Univ Hosp, Univ Hosp, Brno, Czech Republic

[28] Glenfield Hosp, NIHR Cardiovasc Biomed Res Ctr, Leicester, Leics, England

[29] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy

[30] Kyushu Univ, Fukuoka, Japan

[31] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[32] Univ Med & Pharm Carol Davila, Univ & Emergency Hosp, Bucharest, Romania

[33] Chinese Acad Med Sci, Fuwai Hosp, Beijing, Peoples R China

[34] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[35] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[36] Boehringer Ingelheim Pharma Inc, Ridgefield, CT USA

[37] Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany

[38] London Sch Hyg & Trop Med, Dept Med Stat, London, England

[39] Baylor Univ, Med Ctr, Dallas, TX USA

[40] Imperial Coll, London, England

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2020年 / 22卷 / 12期

关键词：

Heart failure with preserved ejection fraction; Sodium– glucose co‐ transporter; 2; inhibitors; Empagliflozin; SPIRONOLACTONE; OUTCOMES;

D O I：

10.1002/ejhf.2064

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 +/- 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41-50%. The mean LVEF (54 +/- 9%) was slightly lower while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.

引用

页码：2383 / 2392

页数：10

共 23 条

[1] Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos S. ;

Jamal, Waheed ;

Salsali, Afshin ;

Schnee, Janet ;

Kimura, Karen ;

Zeller, Cordula ;

George, Jyothis ;

Brueckmann, Martina ;

Zannad, Faiez ;

Packer, Milton ;

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos S. ;

Zannad, Faiez ;

George, Jyothis ;

Brueckmann, Martina .

EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (10) :1279-1287

[2] Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure [J].

Butler, Javed ;

Handelsman, Yehuda ;

Bakris, George ;

Verma, Subodh .

EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (04) :604-617

[3] The perindopril in elderly people with chronic heart failure (PEP-CHF) study [J].

Cleland, John G. F. ;

Tendera, Michal ;

Adamus, Jerzy ;

Freemantle, Nick ;

Polonski, Lech ;

Taylor, Jacqueline .

EUROPEAN HEART JOURNAL, 2006, 27 (19) :2338-2345

[4] Heart failure with preserved ejection fraction: uncertainties and dilemmas [J].

Ferrari, Roberto ;

Boehm, Michael ;

Cleland, John G. F. ;

Paulus, Walter J. S. ;

Pieske, Burkert ;

Rapezzi, Claudio ;

Tavazzi, Luigi .

EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (07) :665-671

[5] Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure [J].

Honigberg, Michael C. ;

Vardeny, Orly ;

Vaduganathan, Muthiah .

CIRCULATION-HEART FAILURE, 2020, 13 (02)

[6]

James SL, 2018, LANCET, V392, P1789, DOI [10.1016/s0140-6736(18)32335-3, 10.1016/S0140-6736(18)32335-3]

[7] Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM [J].

Lewis, Eldrin F. ;

Lamas, Gervasio A. ;

O' Meara, Eileen ;

Granger, Christopher B. ;

Dunlap, Mark E. ;

McKelvie, Robert S. ;

Probstfield, Jeffrey L. ;

Young, James B. ;

Michelson, Eric L. ;

Halling, Katarina ;

Carlsson, Jonas ;

Ofsson, Bertil ;

McMurray, John J. V. ;

Yusuf, Salim ;

Swedberg, Karl ;

Pfeffer, Marc A. .

EUROPEAN JOURNAL OF HEART FAILURE, 2007, 9 (01) :83-91

[8] Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. [J].

Massie, Barry M. ;

Carson, Peter E. ;

McMurray, John J. ;

Komajda, Michel ;

McKelvie, Robert ;

Zile, Michael R. ;

Anderson, Susan ;

Donovan, Mark ;

Iverson, Erik ;

Staiger, Christoph ;

Ptaszynska, Agata .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23) :2456-2467

[9] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [J].

McMurray, J. J. V. ;

Solomon, S. D. ;

Inzucchi, S. E. ;

Kober, L. ;

Kosiborod, M. N. ;

Martinez, F. A. ;

Ponikowski, P. ;

Sabatine, M. S. ;

Anand, I. S. ;

Belohlavek, J. ;

Bohm, M. ;

Chiang, C. -E. ;

Chopra, V. K. ;

de Boer, R. A. ;

Desai, A. S. ;

Diez, M. ;

Drozdz, J. ;

Dukat, A. ;

Ge, J. ;

Howlett, J. G. ;

Katova, T. ;

Kitakaze, M. ;

Ljungman, C. E. A. ;

Merkely, B. ;

Nicolau, J. C. ;

O'Meara, E. ;

Petrie, M. C. ;

Vinh, P. N. ;

Schou, M. ;

Tereshchenko, S. ;

Verma, S. ;

Held, C. ;

DeMets, D. L. ;

Docherty, K. F. ;

Jhund, P. S. ;

Bengtsson, O. ;

Sjostrand, M. ;

Langkilde, A. -M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :1995-2008

[10] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J].

Neal, Bruce ;

Perkovic, Vlado ;

Mahaffey, Kenneth W. ;

de Zeeuw, Dick ;

Fulcher, Greg ;

Erondu, Ngozi ;

Shaw, Wayne ;

Law, Gordon ;

Desai, Mehul ;

Matthews, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) :644-657

← 1 2 3 →